Assessment of glucose-6-phosphate dehydrogenase activity using CareStart G6PD rapid diagnostic test and associated genetic variants in Plasmodium vivax malaria endemic setting in Mauritania

Autoři: Oum kelthoum Mamadou Djigo aff001;  Mohamed Abdallahi Bollahi aff002;  Moina Hasni Ebou aff001;  Mohamed Salem Ould Ahmedou Salem aff001;  Rachida Tahar aff003;  Hervé Bogreau aff004;  Leonardo Basco aff005;  Ali Ould Mohamed Salem Boukhary aff001
Působiště autorů: Unité de recherche Génomes et Milieux, Faculté des Sciences et Techniques, Université de Nouakchott Al-Aasriya, Nouveau Campus Universitaire, Nouakchott, Mauritania aff001;  Centre National de Transfusion Sanguine, Ministère de la Santé, Nouakchott, Mauritania aff002;  UMR 216 MERIT, IRD, Faculté de Pharmacie, Univ. Paris Descartes, Paris, France aff003;  Unité de Parasitologie et d’Entomologie, Institut de Recherche Biomédicale des Armées, IHU-Méditerranée Infection, Marseille, France aff004;  Aix Marseille Univ, IRD, AP-HM, SSA, VITROME, Marseille, France aff005;  IHU-Méditerranée Infection, Marseille, France aff006;  Centre National de Référence du Paludisme, Institut Hospitalo-Universitaire (IHU) Méditerranée Infection, Marseille, France aff007
Vyšlo v časopise: PLoS ONE 14(9)
Kategorie: Research Article
doi: 10.1371/journal.pone.0220977



Primaquine is recommended by the World Health Organization (WHO) for radical treatment of Plasmodium vivax malaria. This drug is known to provoke acute hemolytic anemia in individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency. Due to lack of data on G6PD deficiency, the use of primaquine has been limited in Africa. In the present study, G6PD deficiency was investigated in blood donors of various ethnic groups living in Nouakchott, a P. vivax endemic area in Mauritania.

Methodology/Principal findings

Venous blood samples from 443 healthy blood donors recruited at the National Transfusion Center in Nouakchott were screened for G6PD activity using the CareStart G6PD deficiency rapid diagnostic test. G6PD allelic variants were investigated using DiaPlexC G6PD genotyping kit that detects African (A-) and Mediterranean (B-) variants. Overall, 50 of 443 (11.3%) individuals (49 [11.8%] men and 1 [3.7%] woman) were phenotypically deficient. Amongst men, Black Africans had the highest prevalence of G6PD deficiency (15 of 100 [15%]) and White Moors the lowest (10 of 168, [5.9%]). The most commonly observed G6PD allelic variants among 44 tested G6PD-deficient men were the African variant A- (202A/376G) in 14 (31.8%), the Mediterranean variant B- (563T) in 13 (29.5%), and the Betica-Selma A- (376G/968C) allelic variant in 6 (13.6%). The Santamaria A- variant (376G/542T) and A variant (376G) were observed in only one and two individuals, respectively. None of the expected variants was observed in 8 (18.2%) of the tested phenotypically G6PD-deficient men.


This is the first published data on G6PD deficiency in Mauritanians. The prevalence of phenotypic G6PD deficiency was relatively high (11.3%). It was mostly associated with either African or Mediterranean variants, in agreement with diverse Arab and Black African origins of the Mauritanian population.

Klíčová slova:

Medicine and health sciences – Hematology – anémia – Hemolytic anemia – Glucose-6-phosphate dehydrogenase deficiency – Pharmacology – Drugs – Primaquine – Parasitic diseases – Malaria – Tropical diseases – Health care – Blood donors – People and places – Population groupings – Ethnicities – African people – Geographical locations – Africa – Mauritania – Biology and life sciences – Parasitology – Parasite groups – Apicomplexa – Plasmodium – Genetics – Mutation – Point mutation


1. Mint Lekweiry K, Basco LK, Ould Ahmedou Salem MS, Hafid JE, Marin-Jauffre A, Ould Weddih A, et al. Malaria prevalence and morbidity among children reporting at health facilities in Nouakchott, Mauritania. Trans R Soc Trop Med Hyg. 2011;105:727–733. doi: 10.1016/j.trstmh.2011.09.004 22019287

2. Deida J, Tahar R, Khalef Y, Mint Lekweiry K, Hmeyade A, Ould Khairy ML, et al. Oasis malaria, northern Mauritania. Emerg Infect Dis. 2019; 25(2):282–289.

3. Ould Ahmedou Salem MS, Basco LK, Ouldabdellahi M, Mint Lekweiry K, Konate L, Faye O, et al. Malaria-associated morbidity during the rainy season in Saharan and Sahelian zones in Mauritania. Acta Trop. 2015;152:1–7. doi: 10.1016/j.actatropica.2015.08.005 26276697

4. Ba H, Duffy CW, Ahouidi AD, Deh YB, Diallo MY, Tandia A, et al. Widespread distribution of Plasmodium vivax malaria in Mauritania on the interface of the Maghreb and West Africa. Malar J. 2016;15:80. doi: 10.1186/s12936-016-1118-8 26861780

5. Wells TN, Burrows JN, Baird JK. Targeting the hypnozoite reservoir of Plasmodium vivax: the hidden obstacle to malaria elimination. Trends Parasitol 2010;26:145–151. doi: 10.1016/ 20133198

6. United States Food and Drugs Administration. Krintafel (tafenoquine succinate tablets) FDA Advisory Committee Briefing Document. 2018. 129p. [Accessed 14 June 2019]

7. Fernando D, Rodrigo C, Rajapakse S. Primaquine in vivax malaria: an update and review on management issues. Malar J. 2011;10:351. doi: 10.1186/1475-2875-10-351 22152065

8. Watson J, Taylor WRJ, Bancone G, Chu CS, Jittamala P, White NJ. Implications of current therapeutic restrictions for primaquine and tafenoquine in the radical cure of vivax malaria. PLoS Negl Trop Dis 2018;12(4): e0006440. doi: 10.1371/journal.pntd.0006440 29677199

9. Gómez-Manzo S, Marcial-Quino J, Vanoye-Carlo A, Serrano-Posada H, Ortega-Cuellar D, González-Valdez A, et al. Glucose-6-phosphate dehydrogenase: update and analysis of new mutations around the world. Int J Mol Sci. 2016;17(12): 2069.

10. Minucci A, Moradkhani K, Hwang M, Zuppi C, Giardina B, Capoluongo P. Glucose-6-phosphate dehydrogenase (G6PD) mutations database: Review of the “old” and update of the new mutations. Blood Cells Mol Dis. 2012;48:154–165. doi: 10.1016/j.bcmd.2012.01.001 22293322

11. Carter N, Pamba A, Duparc S, Waitumbi JN. Frequency of glucose-6-phosphate dehydrogenase deficiency in malaria patients from six African countries enrolled in two randomized anti-malarial clinical trials. Malar J. 2011;10:241. doi: 10.1186/1475-2875-10-241 21849081

12. Nafa K, Reghis A, Osmani N, Baghli L, Ait-Abbes H, Benabadji M, et al. At least five polymorphic variants account for the prevalence of glucose 6-phosphate deficiency in Algeria. Hum Genet 1994;94:513–517. 7959686

13. Lacerda MV, Fragoso SC, Alecrim MG, Alexandre MA, Magalhaes BM, Siqueira AM et al. Postmortem characterization of patients with clinical diagnosis of Plasmodium vivax malaria: to what extent does this parasite kill? Clin Infect Dis 2012;55:e67–74. 22772803

14. Howes RE, Dewi M, Piel FB, Monteiro WM, Battle KE, Messina JP, et al. Spatial distribution of G6PD deficiency variants across malaria-endemic regions. Malar J. 2013;12:418. doi: 10.1186/1475-2875-12-418 24228846

15. Tan IK, Whitehead TP. Automated fluorometric determination of glucose-6-phosphate dehydrogenase (G6PD) and 6-phosphogluconate dehydrogenase (6PGD) activities in red blood cells. Clin Chem 1969;15:467–478. 4389159

16. Beutler E. A series of new screening procedures for pyruvate kinase deficiency, glucose-6-phosphate dehydrogenase deficiency, and glutathione reductase deficiency. Blood 1966;28:553–562. 5923607

17. Van Noorden CJ, Vogels IM. A sensitive cytochemical staining method for glucose-6-phosphate dehydrogenase activity in individual erythrocytes. II. Further improvements of the staining procedure and some observations with glucose-6-phosphate dehydrogenase deficiency. Br J Haematol. 1985;60:57–63. 2408654

18. McNerney R. Diagnostics for developing countries. Diagnostics (Basel). 2015;5(2): 200–209.

19. Ley B, Luter N, Espino FE, Devine A, Kalnoky M, Lube Y et al. The challenges of introducing routine G6PD testing into radical cure: a workshop report. Malar J. 2015;14:377. doi: 10.1186/s12936-015-0896-8 26416229

20. von Fricken ME, Weppelmann TA, Eaton WT, Masse R, Beau de Rochars MVE. Performance of the CareStart glucose-6-phosphate dehydrogenase (G6PD) rapid diagnostic test in Gressier, Haiti. Am. J. Trop Med Hyg. 2014;91(1):77–80. doi: 10.4269/ajtmh.14-0100 24778197

21. Osorio L, Carter N, Arthur P, Bancone G, Gopalan S, Gupta SK, et al. Performance of BinaxNOW G6PD deficiency point-of-care diagnostic in P. vivax-infected subjects. Am J Trop Med Hyg. 2015;92(1): 22–27. doi: 10.4269/ajtmh.14-0298 25385861

22. WHO World malaria report 2017. Geneva, Switzerland, 2017.

23. Mauritania National Statistics Office. General population and housing census, 2013 [in French]. 2013 [cited 2018 Jun 11].

24. Hamed CT, Bollahi MA, Abdelhamid I, Med Mahmoud MA, Ba B, Ghaber S, Habti N, Houmeida A. Frequencies and ethnic distribution of ABO and Rh(D) blood groups in Mauritania: results of first nationwide study. Int J Immunogenet. 2012;39:151–154. doi: 10.1111/j.1744-313X.2011.01064.x 22128837

25. Zúñiga MA, Mejía RE, Sánchez AL, Sosa-Ochoa WH, Fontecha GA. Glucose-6-phosphate dehydrogenase deficiency among malaria patients of Honduras: a descriptive study of archival blood samples. Malar J. 2015;14:308. doi: 10.1186/s12936-015-0823-z 26249834

26. WHO. Glucose-6-phosphate dehydrogenase deficiency. WHO Working Group. Bull World Health Organ 1989;67: 601–611. 2633878

27. MedCalc Statistical Software version 16.4.3. MedCalc Software bvba. Ostend, Belgium; 2016.

28. Wurtz N, Mint Lekweiry K, Bogreau H, Pradines B, Rogier C, Ould Mohamed Salem Boukhary A, et al. Vivax malaria in Mauritania includes infection of a Duffy-negative individual. Malar J. 2011;10:336. doi: 10.1186/1475-2875-10-336 22050867

29. Mint Hamdinou M, Deida J, Ebou MH, El-Ghassem A, Lekweiry KM, Ould Ahmedou Salem MS, et al. Distribution of Duffy blood group (FY) phenotypes among Plasmodium vivax-infected patients in Nouakchott, Mauritania. Trop Med Int Health. 2017;22 (Suppl 1);127–128.

30. Howes RE, Piel FB, Patil AP, Nyangiri OA, Gething PW, Dewi M et al. G6PD deficiency prevalence and estimates of affected populations in malaria endemic countries: a geostatistical model-based map. PLoS Med. 2012; 9(11):e1001339. doi: 10.1371/journal.pmed.1001339 23152723

31. De Araujo C, Migot-Nabias F, Guitard J, Pelleau S, Vulliamy T, Ducrocq R. The role of the G6PD A-376G/968C allele in glucose-6-phosphate dehydrogenase deficiency in the Sereer population of Senegal. Haematologica 2006;91:262–263. 16461316

32. Jalloh A, Jalloh M, Gamanga I, Baion D, Sahr F, Gbakima A, et al. G6PD deficiency assessment in Freetown, Sierra Leone, reveals further insight into the molecular heterogeneity of G6PD A-. J Hum Genet. 2008;53:675–679. doi: 10.1007/s10038-008-0294-y 18452027

33. Ouattara AK, Bisseye C, Elvira Bazie BVJT, Diarra B, Compaore TR, Djigma F, Pietra V, Moret R, Simpore J. Glucose-6-phosphate dehydrogenase (G6PD) deficiency is associated with asymptomatic malaria in a rural community in Burkina Faso. Asian Pacific J Trop Biomed. 2014; 4(8): 655–658.

34. Settin A, Al-Haggar M, Al-Baz R, Yousof H, Osman N. Screening for G6PD Mediterranean mutation among Egyptian neonates with high or prolonged jaundice. Haema 2006; 9(1):83–90.

35. Benmansour I, Moradkhani K, Moumni I, Wajcman H, Hafsia R, Ghanem A, et al. Two new class III G6PD variants [G6PD Tunis (c.920A>C: p.307Gln>Pro) and G6PD Nefza (c.968T>C: p.323 Leu>Pro)] and overview of the spectrum of mutations in Tunisia. Blood Cell Mol Dis. 2013;50:110–114.

36. Dolo A, Maiga B, Guindo A, Diakité SAS, Diakite M, Tapily A et al. Fréquence du déficit en glucose-6-phosphate déshydrogénase (A-376/202) dans trois groupes ethniques vivant en zone d’endémie palustre au Mali. Bull Soc Pathol Exot. 2014;107:165–170. doi: 10.1007/s13149-014-0372-7 24952161

37. Clark TG, Fry AE, Auburn S, Campino S, Diakite M, Green A, et al. Allelic heterogeneity of G6PD deficiency in West Africa and severe malaria susceptibility. Eur J Hum Genet. 2009, 17:1080–1085. doi: 10.1038/ejhg.2009.8 19223928

38. Sirugo G, Predazzi IM, Bartlett J, Tacconelli A, Walther M, Williams SM. G6PD A- deficiency and severe malaria in The Gambia: heterozygote advantage and possible homozygote disadvantage. Am J Trop Med Hyg. 2014;90(5):856–859. doi: 10.4269/ajtmh.13-0622 24615128

39. Laouini N, Bibi A, Ammar H, Kazdaghli K, Ouali F, Othmani R et al. Glucose-6-phosphate dehydrogenase deficiency in Tunisia: molecular data and phenotype-genotype association. Mol Biol Rep. 2013;40:851–856. doi: 10.1007/s11033-012-2124-8 23065279

40. Espino FE, Bibit J-A, Sornillo JB, Tan A, von Seidlein L, Ley B. Comparison of three screening test kits for G6PD enzyme deficiency: implications for its use in the radical cure of vivax malaria in remote and resource-poor areas in the Philippines. PLoS ONE 2016;11(2): e0148172. doi: 10.1371/journal.pone.0148172 26849445

41. Adu-Gyasi D, Asante KP, Newton S, Dosoo D, Amoako S, Adjei G, et al. Evaluation of the diagnostic accuracy of CareStart G6PD deficiency rapid diagnostic test (RDT) in a malaria endemic area in Ghana, Africa. PLoS ONE 2015;10(4):e0125796. doi: 10.1371/journal.pone.0125796 25885097

42. Satyagraha AW, Sadhewa A, Elvira R, Elyazar I, Feriandika D, Antonjaya U et al. Assessment of point-of-care diagnostics for G6PD deficiency in malaria endemic rural eastern Indonesia. PLoS Negl Trop Dis. 2016;10(2):e0004457. doi: 10.1371/journal.pntd.0004457 26894297

43. Roh ME, Oyet C, Orikiriza P, Wade M, Mwanga-Amumpaire J, Boum Y et al. Screening for glucose-6-phosphate dehydrogenase deficiency using three detection methods: a cross-sectional survey in southwestern Uganda. Am J Trop Med Hyg. 2016;95(5):1094–1099. doi: 10.4269/ajtmh.16-0552 27672207

44. Von Fricken ME, Weppelmann TA, Eaton WT, Masse R, Beau de Rochars MVE, Okech BA. Performance of the CareStart glucose-6-phosphate dehydrogenase (G6PD) rapid diagnostic test in Gressier, Haiti. Am J Trop Med Hyg. 2014;91(1):77–80. doi: 10.4269/ajtmh.14-0100 24778197

45. Henriques G, Phommasone K, Tripura R, Peto TJ, Raut S, Snethlage C, et al. Comparison of glucose-6-phosphate dehydrogenase status by fluorescent spot test and rapid diagnostic test in Lao PDR and Cambodia. Malar J. 2018;17:243. doi: 10.1186/s12936-018-2390-6 29929514

46. Kim S, Nguon C, Guillard B, Duong S, Chy S, Sum S, et al. Performance of the CareStart™ G6PD deficiency screening test, a point-of-care diagnostic for primaquine therapy screening. PLoS ONE. 2011;6(12):e28357. doi: 10.1371/journal.pone.0028357 22164279

47. Brito MA, Peixoto HM, Almeida AC, Oliveira MR, Romero GA, Moura-Neto JP et al. Validation of the rapid test Carestart™ G6PD among malaria vivax-infected subjects in the Brazilian Amazon. Rev Soc Bras Med Trop. 2016;49(4):446–455. doi: 10.1590/0037-8682-0134-2016 27598631

48. Monteiro WM, Brito MAM, Lacerda MVG. Accuracy of CareStart™ G6PD rapid diagnostic test: variation in results from different commercial versions. Rev Soc Bras Med Trop. 2017;50(2):282–283. doi: 10.1590/0037-8682-0003-2017 28562773

Článek vyšel v časopise


2019 Číslo 9

Nejčtenější v tomto čísle

Tomuto tématu se dále věnují…


Zvyšte si kvalifikaci online z pohodlí domova

Ulcerative colitis_muž_břicho_střeva
Ulcerózní kolitida
nový kurz

Blokátory angiotenzinových receptorů (sartany)
Autoři: MUDr. Jiří Krupička, Ph.D.

Antiseptika a prevence ve stomatologii
Autoři: MUDr. Ladislav Korábek, CSc., MBA

Citikolin v neuroprotekci a neuroregeneraci: od výzkumu do klinické praxe nejen očních lékařů
Autoři: MUDr. Petr Výborný, CSc., FEBO

Zánětlivá bolest zad a axiální spondylartritida – Diagnostika a referenční strategie
Autoři: MUDr. Monika Gregová, Ph.D., MUDr. Kristýna Bubová

Všechny kurzy